TROPiCS-02
The TROP2 ADC extended survival by about three months in heavily pretreated hormone-positive breast cancer.
PFS 5.5 vs 4.0 months (HR 0.66); OS 14.4 vs 11.2 months (HR 0.79). Approved February 2023. Established ADCs in HR+ disease after chemotherapy, later joined by Dato-DXd (TROPION-Breast01) and T-DXd in HER2-low (DESTINY-Breast04/06).
- Median 5.5 vs 4 months with Sacituzumab govitecan compared with Chemotherapy; about 1.5 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 34 percent lower chance of the event at any given time (hazard ratio 0.66, likely range 0.53 to 0.83).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- Median 14.4 vs 11.2 months with Sacituzumab govitecan compared with Chemotherapy; about 3.2 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 21 percent lower chance of the event at any given time (hazard ratio 0.79, likely range 0.65 to 0.96).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: HR+/HER2- metastatic breast cancer after endocrine therapy, CDK4/6, and 2-4 chemotherapies: sacituzumab govitecan vs chemotherapy. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (HER2); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
543 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | Sacituzumab govitecan | 272 | 5.5 months | 0.66 (0.53–0.83) | 0.0003 | link |
| Chemotherapy | 271 | 4 months | ||||
| Overall survival | Sacituzumab govitecan | — | 14.4 months | 0.79 (0.65–0.96) | 0.02 | — |
| Chemotherapy | — | 11.2 months |
Pages like this
not linked directly; found by shared links- TrialASCENT
Shares Sacituzumab govitecan, TROP2.
- PairingTROP2 PET → TROP2 ADC selection
Shares Sacituzumab govitecan, TROP2.
- PairingCaution: TOP1 ADC immediately after TOP1 ADC
Shares Sacituzumab govitecan, HR-positive / HER2-negative breast cancer.
- IdeaDual-payload ADCs in first line to prevent resistance
- IdeaAlpha radioligands after ADC failure
- PersonSara M. Tolaney
Shares Sacituzumab govitecan, TROP2, HR-positive / HER2-negative breast cancer.
- PersonJoohyuk Sohn
- Key paperASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer
Shares Hope S. Rugo, Sacituzumab govitecan, TROP2.